Waldencast PLC (NASDAQ:WALD - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $4.9714.
Separately, Telsey Advisory Group reduced their price target on Waldencast from $4.00 to $3.00 and set an "outperform" rating for the company in a research report on Wednesday, August 20th.
Check Out Our Latest Analysis on Waldencast
Waldencast Stock Performance
NASDAQ:WALD remained flat at $2.08 during trading hours on Friday. The company's stock had a trading volume of 140,810 shares, compared to its average volume of 201,889. Waldencast has a 52-week low of $1.48 and a 52-week high of $4.18. The company has a quick ratio of 0.66, a current ratio of 1.35 and a debt-to-equity ratio of 0.21. The company's fifty day simple moving average is $1.88 and its 200 day simple moving average is $2.38.
Hedge Funds Weigh In On Waldencast
A number of large investors have recently bought and sold shares of WALD. Geode Capital Management LLC boosted its position in Waldencast by 62.2% during the 2nd quarter. Geode Capital Management LLC now owns 586,566 shares of the company's stock worth $1,437,000 after acquiring an additional 224,905 shares during the last quarter. Simplicity Wealth LLC acquired a new stake in shares of Waldencast in the 1st quarter valued at approximately $360,000. Nuveen LLC acquired a new stake in shares of Waldencast in the 1st quarter valued at approximately $128,000. Jane Street Group LLC acquired a new stake in shares of Waldencast in the 1st quarter valued at approximately $77,000. Finally, McAdam LLC acquired a new stake in shares of Waldencast in the 2nd quarter valued at approximately $56,000. Institutional investors and hedge funds own 41.97% of the company's stock.
About Waldencast
(
Get Free Report)
Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.
Featured Articles
Before you consider Waldencast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waldencast wasn't on the list.
While Waldencast currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
